@RedDyke69@RupertLowe10 Wow. You got into the gene pool whilst the lifeguard wasn’t watching. Mr Lowe is salvation. Those with brains can see that. In your case……….
Hey in all fairness, if I was an 80-year-old fat fuck, riddled with dementia, while wearing a leg brace, a piss bag, shoe lifts & a full diaper, I probably wouldn’t be able to walk a straight line either. However, I could easily be an astronaut.
Jared Golden was the one and only Democrat who voted to continue Donald Trump's war on Iran.
The vote was won by Trump by 214-213.
Won by just one vote, Jared's.
What a scumbag.
I accepted not receiving my State Pension until I’m 67yrs instead of 60yrs because we were told the country couldn’t afford it, but it grates on me now when they have been able to find the money for unknown people that have rocked up on our shores who have never contributed a single penny.
This is wrong & totally unfair.
I think you assume the market is far brighter than it is, Robert. A big and regular mistake you make.
#AVCT’s invention (ie removing the need for an antibody, thus removing the need for an antigen target, thus removing an entire stage of the ADC process, is nothing short of groundbreaking).
Look at the amount of literature around antigen targets (just HER2 is a thesis in itself I find).
Targeting FAP and removing the need for an antigen turns the entire industry on its head.
It took me a very long time to understand it, despite having followed all the soundboard and the watched the spotlights. It’s not simple (I don’t care what anyone says).
If a change can disrupt many (multi billion) business models, it’s only right diligence should take time. Why shouldn’t it? It’s critical to them.
I know what I hold too. I know the management team. I understand the technology as best as I can. I understand the various personalities involved. But I also know the market (including the analysts and the institutions) are nowhere near as tuned in as you think they are. They will follow pharma into the trade. 100%.
That why I’m looking at the structure behind Avacta as much as the process in clinic. I’m expecting more broker changes and more NOMAD changes.
On 8/12/2025 Peel Hunt was listed as NOMAD on the RNS footer ‘Preliminary Data in Faridoxorubicin Phase 1b Trial’.
On 17/12/2025 AVCT’s NOMAD was removed from the RNS footer.
Ironically, the change everyone craves (to ensure the technology is better represented) is well underway imho.
The company and board is a different beast.
As for whether the CEO could have discussed deals in the Q&A.
She’s MORE than bright enough to understand the bounds within which she can operate.
I believe Avacta is on the very cusp of the validation the market craves.
The technology works. AVA6103 is free at this price and AVA6000 in SGC alone is ascribed a chance of success around what did you put it at? 15%?
For a drug which is obliterating the PFS in an indication without a standard of care.
Those on the sidelines can sell it, buy it, short it. I don’t care.
I know what I hold.
As does a massive percentage of Avacta’s TVR.
The share price should be tapping on the door of 100p right now.
I’ve added today. Silence when Richard Hughes is sat next to Chris Coughlin is very different to silence without him sat on the Board.
I am surprised the market hasn’t grasped this.
@SeanDentBsc@onyx_gems@111BEN_111@RAH00084 That’s utterly hilarious.
I would bet a limb @RAH00084 is immeasurably smarter than you, and unlike you he doesn’t need to add his 2nd rate degree to his handle.
As an old mate of mine often said “I ain’t got a degree but I’ve employed dozens who have !”
Pipe down! #avct
@IndiaWilloughby@SolidusSna19226 India “knows” she’s a woman.
All the rest of us know he’s a bloke who is seriously #MENTALLYILL
It could stop there if he would keep his delusions to himself ….
BUT HE DOESN’T DOES HE ?